GlaxoSmithKline has withdrawn its European application for Votrient for use in ovarian cancer, after phase III trials failed to prove the drug's effectiveness. Votrient (pazopanib) is already ...

Also included in the acquisition is Votrient, Tykerb and Arzerra, products which all lag behind the leaders in their particular cancer sub-types, but which Novartis will aim to revive, using its ...

After the successful launch of Tykerb in 2008, they expanded their presence further by introducing two new segments, Kidney Cancer and Hematology with launch of Votrient and Revolade.In 2012 ...

The drug is therapeutically equivalent to Novartis' Votrient... India & EFTA: Trade Boost, Investment, Business Desk India sets up an EFTA desk to enhance trade and investment with the bloc. The move ...

Angiogenesis, the formation of new blood vessels from preexisting one, represents a critical process for oxygen and nutrient supply to proliferating cells, therefore promoting tumor growth and ...

Most cancers are named after the part of the body where the cancer first begins, and kidney cancer is no exception. Kidney cancer begins in the kidneys—two large, bean-shaped organs—one located to the ...